Skip to main content

The GBP5 protein detection in tuberculosis antigen-stimulated blood and its comparison with interferon-gamma release assay

Journal
BMC infectious diseases (Q1)
Published
19 August 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Ze-Feng Li, Liang Zhu, Meng-Ting Li, Xiao-Fang Yu, Yu-Ling Wu, Xiang-Yang Yao, et al.
PMID
43035666
DOI
10.1186/s12879-026-14041-8

Why clinicians should know about it

  • Picked for Biochemistry (medical) (paper of the day, 19 November 2026): Clinical assay validation reports precision, detection limits, and interference

Abstract

BACKGROUND: A major challenge in tuberculosis control is distinguishing latent infection from active disease, creating an urgent need for more precise and sensitive diagnostics. Recent literature has suggested that guanylate-binding protein 5 (GBP5) may serve as biomarkers of tuberculosis (TB) diagnosis. The aim of this study was to evaluate a GBP5 assay in TB antigen-stimulated blood and to compare its analytical and diagnostic performance with traditional interferon-gamma release assay (IGRA). METHODS: The analytical performance of the newly developed GBP5 chemiluminescence assay (CLIA) was evaluated, including the limit of detection, precision, and interference studies. A total of 571 participants, including 183 TB patients, 69 latent tuberculosis infection (LTBI) individuals and 319 control participants, were enrolled in the study. The whole blood was collected and detected using IGRA and GBP5-CLIA. RESULTS: A chemiluminescence-based GBP5 assay was demonstrated, with a measurement range of 97.66-50,000 pg/mL, a limit of detection of 11.37 pg/mL. The intra-assay precision coefficient of variation was less than 5%, and interference rates remained within ± 10% in the presence of haemoglobin (≤ 5000 mg/dL) and bilirubin (≤ 300 mg/dL), indicating high sensitivity, precision, and good anti-interference capability. In the clinical cohort, GBP5 expression in stimulated whole blood was significantly greater in active tuberculosis (aTB) patients than in non-TB individuals (p < 0.001). Receiving operating characteristic analysis revealed that GBP5 achieved an area under the curve (AUC) of 0.8821 (95% CI, 0.8511 to 0.9132) for diagnosing aTB, with a sensitivity of 85.8% and specificity of 83.4%, which is comparable to that of IGRA (AUC = 0.9085). Furthermore, GBP5 demonstrated a moderate ability to discriminate aTB from latent TB infection (LTBI) (AUC = 0.667, sensitivity 63.39%, specificity 67.16%). CONCLUSIONS: The results of this study indicate that the GBP5 CLIA assay is a potential test for aTB diagnosis and LTBI screening. CLINICAL TRIAL REGISTRATION: Not applicable.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.